Evergen

Executive Summary

Evergen is a private synthetic biology company headquartered in San Diego, founded in 2020, that specializes in developing customized regenerative biomaterial solutions for medical applications. The company partners with Original Equipment Manufacturers (OEMs) to accelerate the design, development, and manufacturing of biomaterials that promote healing, accelerate recovery, and prevent complications. By starting from patient needs, Evergen aims to enhance patient lives through tailored regenerative solutions. The company operates in the metabolic and synthetic biology sectors, positioning itself at the intersection of advanced materials science and medical device innovation. Despite being relatively young and with limited public information on funding or revenue, Evergen's focus on OEM partnerships and regenerative medicine aligns with growing market demand for advanced wound care and implantable biomaterials. The company's business model, which leverages existing manufacturing and distribution channels of OEMs, may enable faster market penetration and reduced capital expenditure. However, the lack of disclosed milestones, clinical data, or commercial traction makes it difficult to assess its current maturity. The competitive landscape includes established players in regenerative medicine and biomaterials, but Evergen's customization approach could provide a differentiation. Overall, the company appears to be in an early stage with promising potential, contingent on its ability to secure partnerships and regulatory clearances.

Upcoming Catalysts (preview)

• Q3 2026First Commercial OEM Partnership Announced60% success
• Q4 2026FDA 510(k) Clearance for Lead Biomaterial Product40% success
• Q2 2026Series A Funding Round Completion50% success